[Immediate and long-term results of brachytherapy in complex treatment for esophageal cancer].

For treatment of cancer of the thoracic esophagus, the method of neoadjuvant chemoradiotherapy (CRT) with a use of intraluminal brachytherapy (BT) was performed. The study included 51 patients (mean age 56.9 ± 4.

[Experience of the use of endovideotechnology in surgical treatment of esophageal cancer].

An investigation included 33 patients with cancer of thoracal section of the esophagus at the age from 42 to 74 years old. A surgical method of treatment was applied as only one in 13 patients and methods of nonadjuvant chemoradiation therapy were used for 20 patients. A hybrid minimally invasive esophagectomy (laparoscopic mobilization of the stomach and right-side thoracotomy) was performed on 16 patients.

[Conservative treatment of locally advanced and inoperable esophageal cancer: possible methods and future directions].

This is an analysis of treatment results data for conservative (endosurgical and radiation therapy) treatment of patients with inoperable locally advanced esophageal cancer receiving therapy in 1990-2011. The original treatment tactics including recanalization of tumor-compressed esophageal lumen (argon plasma coagulation +/- high-frequency surgery or chemical tumor necrolysis) with consequent combined radiotherapy resulted in clinical response in 79,5% of cases, 89,3% of patients retained the possibility of enteral nutrition. One-year overall survival (OS) was 68,9% (58,8% in patients receiving combined radiotherapy), 2-year OS was 22,7% and 21,2% respectively.

[Effectiveness of intensive preoperative radiotherapy of locally- advanced breast tumors].

The investigation was concerned with the effectiveness of intensive preoperative radiotherapy (IPRT) in 423 patients with locally-advanced breast tumors (pT1-2N0M0) after radical surgery. No significant effect on overall or recurrence-free survival (pT1N0M0) was observed following IPRT as a component of combination and complex therapy. Overall and recurrence-free survival (pT2N0M0) was higher (p < 0.